Obeda Injection: Dr. Reddy's Generic Semaglutide in India — Complete Guide
Obeda is Dr. Reddy's Laboratories' generic semaglutide injection launched in India post-patent expiry. Learn how it works, pricing, dosing, and how it compares to Ozempic.
If your doctor has mentioned Obeda as a weight loss or diabetes treatment option, you are looking at one of the newest GLP-1 medicines to reach Indian pharmacies. Dr. Reddy's Laboratories, one of India's most trusted pharmaceutical companies, launched Obeda following the semaglutide patent expiry on March 20, 2026.
This guide explains what Obeda is, how it works, what it costs, and what to expect when you start it.
Important: Always consult your healthcare provider before starting any medication. This article is for informational purposes only.
What Is Obeda?
Obeda is Dr. Reddy's brand name for semaglutide — the active molecule found in Ozempic (diabetes) and Wegovy (weight loss). It belongs to a class of medicines called GLP-1 receptor agonists.
GLP-1 is a hormone your gut naturally produces after eating. It tells your brain you are full, slows stomach emptying, and prompts the pancreas to release insulin when blood sugar rises. Semaglutide mimics this hormone but lasts a full week per dose — far longer than your body's natural version.
Obeda is approved for:
- Type 2 diabetes — improving blood sugar control alongside diet and exercise
- Chronic weight management — for adults with obesity or with overweight and at least one related health condition such as high blood pressure or type 2 diabetes
Dr. Reddy's: Why It Matters Who Makes It
Dr. Reddy's Laboratories is not a small player. Founded in Hyderabad in 1984, it is one of India's largest pharmaceutical companies with a global presence and a strong track record in producing high-quality generics. Its medicines are approved by the US FDA, European EMA, and India's DCGI.
When a company like Dr. Reddy's launches a generic, it carries a level of manufacturing credibility that matters — especially for an injectable medicine like semaglutide, where consistency in formulation and sterility standards are critical.
Obeda Pricing in India
| Product | Manufacturer | Price (approx.) |
|---|---|---|
| Obeda 2mg pen (1.5ml) | Dr. Reddy's | ₹3,780–₹4,200 |
| Sematrinity (0.5mg pen) | Sun Pharma | ~₹1,500–₹2,500 |
| Semaglyn (various) | Zydus Lifesciences | ~₹1,500–₹3,000 |
| Ozempic 1mg (imported) | Novo Nordisk | ₹12,000–₹18,000+ |
Obeda's pricing makes semaglutide treatment significantly more accessible for Indian patients compared to imported alternatives. The 2mg pen (1.5ml) at ₹4,200 MRP — typically discounted to around ₹3,780 — puts it in the same affordability range as other Indian generic brands.
How Obeda Works
Once injected, semaglutide binds to GLP-1 receptors throughout your body and produces several effects:
In your brain: Appetite signals are suppressed. Most people notice they feel full faster and have fewer cravings — especially for high-calorie, high-fat foods.
In your stomach: Digestion slows down. Food stays in your stomach longer, which prolongs the feeling of fullness after meals.
In your pancreas: Insulin release is stimulated when blood sugar rises. Glucagon (which raises blood sugar) is reduced. This two-sided action improves blood sugar control in type 2 diabetes.
Long-term weight effect: When appetite reduces and you eat less consistently over weeks and months, the body draws on stored fat for energy. This is how GLP-1 medicines produce meaningful, sustained weight loss.
Obeda Dosing — How It Works
Semaglutide is always started at a low dose and gradually increased. This slow escalation significantly reduces nausea and other side effects. Your doctor will determine the right schedule for you, but the standard approach is:
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 0.25 mg weekly | Initiation — body adjustment |
| 5–8 | 0.5 mg weekly | Maintenance start |
| 9–12 | 1 mg weekly | Increased effect |
| 13+ | 2 mg weekly | Full maintenance dose |
Not everyone needs to reach 2mg. Your doctor will adjust based on your response and how well you tolerate the medicine.
What to Expect in the First Few Weeks
Week 1–2: Most people notice some reduction in appetite. Nausea is common in the first week — usually mild and short-lived.
Week 3–4: Nausea typically eases as your body adjusts to the medicine. Appetite suppression becomes more consistent.
Week 5–8: At the 0.5mg dose, many people begin noticing a meaningful change in how much they eat at each meal.
Month 3 onwards: Weight loss tends to become more noticeable. Blood sugar improvements (in those with type 2 diabetes) usually appear within the first 4–6 weeks.
Clinical trial data for semaglutide (the molecule in Obeda) shows average weight loss of approximately 15% of body weight over 68 weeks at the 2.4mg weekly dose. Results vary based on diet, activity level, and individual response.
Common Side Effects
Like all GLP-1 medicines, Obeda's most common side effects are gastrointestinal:
- Nausea — most common, especially in the first few weeks
- Vomiting — less frequent, usually linked to nausea
- Diarrhoea or constipation
- Reduced appetite (this is also part of how the medicine works)
- Stomach discomfort or burping
Most of these improve within 4–6 weeks. Eating smaller meals, avoiding fatty or very rich food, and staying hydrated helps manage them.
Serious but rare side effects include pancreatitis, kidney changes, and gallbladder problems. Contact your doctor immediately if you experience severe abdominal pain.
Who Should Not Take Obeda
Obeda is not suitable for everyone. Do not take it if you have:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- Severe gastrointestinal disease (e.g., gastroparesis)
- Pregnancy or planning to become pregnant
- Type 1 diabetes — GLP-1 medicines are not approved for this condition
Always disclose your full medical history and all medications you take to your doctor before starting Obeda.
Obeda vs Other Indian Generic Semaglutides
All Indian generic semaglutides contain the same active molecule. Here is how the key brands compare:
| Brand | Maker | Pen Type | Available strengths |
|---|---|---|---|
| Obeda | Dr. Reddy's | Pre-filled pen | 2mg/1.5ml |
| Sematrinity | Sun Pharma | Pre-filled pen | 0.5mg, 1mg, 2mg |
| Semaglyn | Zydus + Lupin | Reusable adjustable pen | 0.25mg–2.4mg (one pen) |
| Noveltreat | Sun Pharma | Pre-filled pen | 0.5mg, 1mg, 2.4mg |
The reusable adjustable pen (Semaglyn) is a practical advantage for dose escalation. Pre-filled pens (Obeda, Sematrinity, Noveltreat) are more familiar to most patients and healthcare providers. The best option depends on your doctor's preference and your dose stage.
Tracking Your Obeda Journey
Staying consistent with a once-weekly injection, especially during dose escalation, benefits from simple tracking. Knowing which day you injected, how you felt, and whether your appetite changed week to week gives you useful information to bring to your next clinical review.
WeightEasy is designed for exactly this — tracking your GLP-1 dose cycle, logging weight changes, and noting side effects over time. It works with any brand of semaglutide, including Obeda.
Final Takeaway
Obeda brings Dr. Reddy's manufacturing quality to a medicine — semaglutide — that has become one of the most clinically effective treatments for obesity and type 2 diabetes available today. With the semaglutide patent now expired in India, the barrier is cost and access, not chemistry.
If your doctor has prescribed Obeda or recommended it as an option, the clinical evidence behind the molecule is strong. Start at the lowest dose, follow the escalation schedule, and give it at least 12 weeks to assess the full effect.
Consult your healthcare provider before starting any medication.
Sources
- PharmEasy product listing: Obeda 2mg Pre Filled Pen — Dr. Reddy's Laboratories Ltd — https://pharmeasy.in
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. https://doi.org/10.1056/NEJMoa2032183
- Marso SP et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM. https://doi.org/10.1056/NEJMoa1607141
- Drugs.com — Semaglutide (Ozempic, Wegovy) information. https://www.drugs.com/semaglutide.html
- Dr. Reddy's Laboratories — Company profile and product portfolio. https://www.drreddys.com
FAQ
What is Obeda?
Obeda is a generic semaglutide injection developed and marketed by Dr. Reddy's Laboratories in India. It is a once-weekly GLP-1 receptor agonist, the same class as Ozempic and Wegovy, approved for type 2 diabetes and chronic weight management.
How much does Obeda cost in India?
Obeda 2mg pre-filled pen (1.5ml) is priced at ₹4,200 with a 10% discount available on platforms like PharmEasy, bringing it to approximately ₹3,780. This is significantly less expensive than imported Ozempic.
Is Obeda the same as Ozempic?
Obeda contains the same active molecule — semaglutide — as Ozempic and Wegovy. The clinical evidence is the same. The difference is that Obeda is manufactured in India by Dr. Reddy's Laboratories, making it far more affordable for Indian patients.
How do I use the Obeda pre-filled pen?
Obeda comes as a pre-filled injection pen. You inject it once a week, on the same day each week, under the skin (subcutaneous) in the abdomen, thigh, or upper arm. Always follow your doctor's instructions for dose escalation.
Who should not take Obeda?
Obeda is not recommended for people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Consult your doctor before starting. It is not approved for use in pregnancy.